AWE
VRTX icon

Avidian Wealth Enterprises’s Vertex Pharmaceuticals VRTX Stock Holding History

Avidian Wealth Enterprises’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$775K Buy
1,735
+381
+28% +$178K 0.02% 337
2025
Q4 		$614K Buy
1,354
+97
+8% +$41.8K 0.02% 329
2025
Q3 		$492K Buy
1,257
+65
+5% +$27.2K 0.02% 369
2025
Q2 		$531K Sell
1,192
-33
-3% -$15.2K 0.02% 321
2025
Q1 		$594K Buy
1,225
+25
+2% +$11.7K 0.03% 279
2024
Q4 		$483K Buy
1,200
+58
+5% +$26.9K 0.02% 298
2024
Q3 		$531K Sell
1,142
-111
-9% -$53.3K 0.02% 288
2024
Q2 		$587K Buy
1,253
+740
+144% +$321K 0.02% 258
2024
Q1 		$214K Buy
+513
New +$217K 0.01% 411
2022
Q1 		– Sell
-985
Closed -$216K – 581
2021
Q4 		$216K Buy
+985
New +$192K 0.01% 481
2018
Q4 		– Sell
-6,108
Closed -$1.18M – 119
2018
Q3 		$1.18M Buy
6,108
+404
+7% +$71.9K 0.37% 28
2018
Q2 		$969K Buy
+5,704
New +$884K 0.31% 32

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Avidian Wealth Enterprises's VRTX Position: Q1 2026 in Review

Avidian Wealth Enterprises increased its Vertex Pharmaceuticals (VRTX) stake by 28% in Q1 2026, buying an estimated $178K and bringing the position to 1,735 shares worth $775K. The position accounts for 0.02% of the portfolio, ranked #337.

Avidian Wealth Enterprises first reported a position in VRTX in Q2 2018 and has held it in 12 quarters since. The position peaked at $1.18M in Q3 2018. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Avidian Wealth Enterprises held 1,735 shares of Vertex Pharmaceuticals worth $775K as of Q1 2026.
  • Avidian Wealth Enterprises bought 381 Vertex Pharmaceuticals shares in Q1 2026, an estimated $178K.
  • Vertex Pharmaceuticals made up 0.02% of Avidian Wealth Enterprises's portfolio in Q1 2026, its #337 holding.
  • Avidian Wealth Enterprises first reported a position in Vertex Pharmaceuticals in Q2 2018 and has held it in 12 quarters since.
  • Avidian Wealth Enterprises's Vertex Pharmaceuticals position peaked at $1.18M in Q3 2018.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Avidian Wealth Enterprises's 13F filing for Q1 2026, filed 7 May 2026.